Analysts forecast that Aduro BioTech Inc (NASDAQ:ADRO) will report earnings of ($0.13) per share for the current quarter, Zacks reports. Three analysts have made estimates for Aduro BioTech’s earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.09). Aduro BioTech reported earnings per share of ($0.23) in the same quarter last year, which indicates a positive year-over-year growth rate of 43.5%. The firm is scheduled to announce its next earnings report on Thursday, August 6th.
On average, analysts expect that Aduro BioTech will report full-year earnings of ($0.64) per share for the current fiscal year, with EPS estimates ranging from ($0.84) to ($0.50). For the next financial year, analysts forecast that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.22) to ($0.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last posted its earnings results on Monday, May 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. Aduro BioTech had a negative net margin of 243.93% and a negative return on equity of 86.31%. The firm had revenue of $13.95 million during the quarter, compared to analysts’ expectations of $8.81 million.
A number of research firms have weighed in on ADRO. Zacks Investment Research cut shares of Aduro BioTech from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. HC Wainwright upped their price objective on shares of Aduro BioTech from $3.75 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. They noted that the move was a valuation call. Oppenheimer began coverage on shares of Aduro BioTech in a research report on Friday, June 5th. They set a “hold” rating for the company. Finally, ValuEngine upgraded shares of Aduro BioTech from a “hold” rating to a “buy” rating in a research report on Friday, May 1st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Aduro BioTech presently has a consensus rating of “Hold” and a consensus price target of $4.92.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Vivo Capital LLC purchased a new stake in shares of Aduro BioTech in the first quarter valued at about $14,025,000. Renaissance Technologies LLC grew its holdings in shares of Aduro BioTech by 69.4% in the fourth quarter. Renaissance Technologies LLC now owns 4,638,310 shares of the biotechnology company’s stock valued at $5,473,000 after purchasing an additional 1,900,110 shares during the period. Baillie Gifford & Co. grew its holdings in shares of Aduro BioTech by 1.1% in the first quarter. Baillie Gifford & Co. now owns 4,279,324 shares of the biotechnology company’s stock valued at $11,725,000 after purchasing an additional 47,068 shares during the period. Ikarian Capital LLC grew its holdings in shares of Aduro BioTech by 97.9% in the first quarter. Ikarian Capital LLC now owns 3,638,000 shares of the biotechnology company’s stock valued at $9,968,000 after purchasing an additional 1,799,472 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Aduro BioTech in the first quarter valued at about $4,627,000. Institutional investors and hedge funds own 48.14% of the company’s stock.
Shares of ADRO traded up $0.06 during trading hours on Tuesday, hitting $2.24. The stock had a trading volume of 1,003,200 shares, compared to its average volume of 934,267. The company has a debt-to-equity ratio of 0.52, a quick ratio of 9.13 and a current ratio of 9.13. The firm has a 50-day moving average price of $2.66 and a 200 day moving average price of $2.41. Aduro BioTech has a fifty-two week low of $0.90 and a fifty-two week high of $4.04. The firm has a market capitalization of $176.23 million, a price-to-earnings ratio of -2.73 and a beta of 0.35.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Further Reading: Initial Coin Offerings entail a high degree of risk
Get a free copy of the Zacks research report on Aduro BioTech (ADRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.